Prasad NK. Two diseases with one hit: Inhibiting a potential diabetes target to reduce cancer risk and to improve anti-cancer therapy. Curr Cancer Ther Rev 2009; 5(2): 111-21.
Guppy A, Jamal-Hanjani M, Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 2011; 7(6): 727-36.
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-74.
Karnevi E, Said K, Andersson R, Rosendahl AH. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 2013; 13: 235.
Salis O, Bedir A, Ozdemir T, Okuyucu A, Alacam H. The relationship between anticancer effect of metformin and the transcriptional regulation of certain genes (CHOP, CAV-1, HO-1, SGK-1 and Par-4) on MCF-7 cell line. Eur Rev Med Pharmacol Sci 2014; 18(11): 1602-9.
Cha JH, Yang WH, Xia W, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell 2018; 71(4): 606-20.e7.
Golias T, Kery M, Radenkovic S, Papandreou I. Microenviron-mental control of glucose metabolism in tumors by regulation of pyruvate dehydrogenase. Int J Cancer 2018; 144(4): 674-86.
Restifo D. Williams JS2, Garacci E, Walker RJ, Ozieh MN, Egede LE. Differential relationship between colorectal cancer and diabetes in a nationally representative sample of adults. J Diabetes Complications 2018; 32(9): 819-23.
Wu D, Hu D, Chen H, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature 2018; 559(7715): 637-41.
Seliger C, Luber C, Gerken M, Schaertl J, Proescholdt M. Use of metformin and survival of patients with high-grade glioma. Int J Cancer 2018; 144(2): 273-80.